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Abstract
Background: New regulations by the Swiss Federal Food Safety and Veterinary Office provide for the monitoring of
breed health by Swiss breeding clubs. In collaboration with the Swiss Bernese Mountain Dog Club, the purpose of
this study was to investigate the causes of death in purebred dogs registered by the club and born in 2001 and 2002.
Results: Of a total of 1290 Bernese mountain dogs (BMDs) born in 2001 and 2002 in Switzerland, data was collected
from owners and veterinarians using a questionnaire designed for this study from 389 dogs (30.2 %). By the end of the
study, 381/389 dogs (97.9 %) had died. The median life expectancy of all dogs was 8.4 years (IQR, 6.9–9.7). Female dogs
had a significantly longer median survival (8.8 years; IQR, 7.1–10.3) than male dogs (7.7 years; IQR, 6.6–9.3) (P < 0.00). The
cause of death was unknown in 89/381 dogs (23.4 %). For the remaining dogs, the most frequent causes of death
were neoplasia (222/381, 58.3 %), degenerative joint disease (16/381, 4.2 %), spinal disorders (13/381, 3.4 %), renal injury
(12/381, 3.1 %), and gastric or mesenteric volvulus (7/381, 1.8 %). However, large numbers of dogs were diagnosed
with neoplasia without histopathologic or cytologic confirmation. Dogs with neoplasms had a shorter median survival
than dogs with other disorders. The shortest median survival (6.8 years) was found for dogs with renal injury.
Conclusions: Findings of this study confirm a high prevalence of neoplasia and associated low life expectancy in
BMDs. The results underline a need for more widespread precise diagnostics and further research on malignant
tumours in this breed to improve overall breed health.
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Background
Previous studies have demonstrated a relatively low life
expectancy and high incidence of neoplasia in the Bernese
mountain dog (BMD) [1–4]. Indeed, the BMD was the
most short-lived breed in 1 study, with a mean life expec-
tancy of 6.8 years [5]. More recent studies reported mean
and median life expectancies of 7.1 and 7.0–8.0 years, re-
spectively, compared with a calculated mean and median
expectancy for all breeds of 10 and 11 years, respectively
[1, 4, 6, 7]. Although larger breeds have been shown to
have a lower average age at death than smaller breeds
[1, 6, 8–10], the life expectancy of BMDs remains low
when compared with breeds of similar size, such as flat
coated retrievers (mean, 9.5 years) or German shepherd
dogs (mean, 10.3 years) [1, 6]. In addition, some previous
studies indicate a lower life expectancy of male BMDs
compared to females [5]. Moreover, several studies have
shown disparate longevity in dogs of all breeds based on
sex and neutering, including greater longevity for neutered
females compared to males or intact females [6], and
shortest longevity for intact females compared to males
or neutered females [10].
Several authors explain the low life expectancy in the
BMD by the high incidence of neoplastic diseases [4, 7].
Indeed, previous studies reported neoplasia as the cause
of death in 28.1–55.1 % of BMDs [1, 3–5] compared to
14.5–16.5 % in the overall dog population [1, 6, 10]. In
particular, BMDs are predisposed to histiocytic sarcoma
(HS), which is highly aggressive and associated with a
very poor prognosis [4, 7, 11, 12]. Although previous
studies have shown inheritance of HS in BMDs [13, 14],
the exact mode of inheritance is unclear and an oligogenic
transmission mode has been proposed [12]. In 1 study,
examining the cause of death in a BMD population in
Denmark in 2010, neoplasia (42.1 %) was the most
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frequently reported cause followed by old age (10.3 %),
kidney disease (6.9 %), infection (5.9 %), skeletal disorders
(5.2 %), heart disease (3.8 %) and behavioural disorders
(3.5 %) [7].
Recent new regulations have been introduced by the
Swiss Federal Food Safety and Veterinary Office (FSVO)
to restrict breeding of animals with inherited defects,
which are associated with pain or suffering [15]. This
new administrative order also obliges breed organisa-
tions to systematically monitor their breed’s health and
take measures to reduce or prevent breeding of traits
that may have a negative impact on breed health. In
consequence, the Swiss Bernese Mountain Dog Club
launched an appeal to investigate the current state of the
breed’s health in Switzerland and establish a survey sys-
tem to prospectively gather epidemiologic health data.
The aim of this study was to investigate life expectancy
and causes of death of BMDs born in Switzerland.
Methods
Dog population
Data of purebred BMDs, born in Switzerland in 2001
and 2002 and registered with the Swiss Bernese Moun-
tain Dog Club, were collected. Of a total of 1290 dogs,
owners of 402 dogs (31.2 %) had participated in a previ-
ous study evaluating disease prevalence in BMDs [16],
based on questionnaires completed by veterinarians and
owners. Of these, data on the cause of death was avail-
able for 196 dogs. For the present study, owners of the
remaining 206 dogs were contacted and invited to par-
ticipate in the study to complete data on causes of death
for all 402 dogs. Those agreeing were asked to have a
questionnaire completed by their veterinarian at the
start of the study (March 2012) and at each subsequent
veterinary consultation until the end of the study (30
June 2014).
The questionnaire was modified from that used in the
previous study to include only data relevant to the cause
of death. The main body of the questionnaire identified
the animal by name and by the 15-digit microchip num-
ber from the Animal Identity Services AG (ANIS), and
served to classify diseases both by the affected organ sys-
tem and the pathophysiologic disease process involved.
In addition, veterinarians were asked to formulate a
definitive, suspected or symptomatic diagnosis in a
free-text field. Check boxes are available to identify the
types of examinations conducted during consultation,
treatments given and the clinical outcome. Each ques-
tionnaire was signed by both the owner and the veteri-
narian, confirming consent to study participation. The
questionnaire was made available in German, French
and English and was sent with a letter explaining the
study aims to all owners of the 206 dogs in March
2012. Two months later, a reminder was sent to owners
not responding to the initial contact and an attempt
was made to contact those owners by telephone. A final
renewed attempt to contact nonresponding owners was
made in June 2013. The study was submitted for approval
to the Cantonal Veterinary Services of the Canton of
Berne and was determined exempt from the need for
review, according to the Swiss Federal Welfare Act of
December 16th 2005 and adheres. The study adheres
to ARRIVE guidelines for reporting animal research.
Encoding and reliability of diagnoses
Data collected from the completed questionnaires, the
internal surveillance of the Swiss Bernese Mountain Dog
Club and the ANIS Company were combined with data
from the previous study [16] using a hierarchical coding
system. Data regarding the cause of death or diseases
identified at the time of death/euthanasia, sex and age
at death were analysed. The coding system assigned
diseases reported by veterinarians or owners into 1 of
12 organ systems: musculoskeletal, cardiovascular,
respiratory, gastrointestinal, urogenital, integumentary,
neurological, haemolymphatic, endocrine, ocular, multi-
organ system, and other, whereby a multi-organ disorder
was allocated if more than 1 system was identified. Disease
processes were encoded into 1 of 12 classifications as
inflammatory/infectious, metabolic/toxic, traumatic, neo-
plastic, degenerative, idiopathic, congenital, alimentary,
immunologic/allergic, mechanical (such as organ displace-
ments or obstructions), and symptomatic conditions
when no clear etiologic process was identified. Data on
the specific causes of death given by veterinarians were
also collected.
The reliability of diagnoses was categorized as poor
(cause of death reported by the owner without veterinary
data or cause of death unknown), moderate (cause of
death based on veterinary suspected diagnosis and clin-
ical examination alone), high (cause of death based on
veterinary suspected diagnosis, clinical examination and
further supporting diagnostic examinations) or excellent
(cause of death based on veterinary suspected diagnosis,
clinical examination and confirmation by relevant fur-
ther diagnostic examinations, whereby cytology and/or
histology was necessary for the diagnosis of neoplasia).
No distinction in reliability of diagnoses was made be-
tween primary-care and referral veterinarians.
Statistical analysis
Data analysis was performed using statistical software
(NCSS 9, www.ncss.com, and MedCalc Statistical Software
version 15.4, MedCalc Software bvba, Ostend, Belgium;
https://www.medcalc.org; 2015). Descriptive statistics
were used to evaluate survival based on sex, reliability
of diagnoses, organ system, disease process and specific
diagnoses. Normality was evaluated using D’Agostino-
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Pearson tests. Kaplan-Meier survival analyses were per-
formed to estimate and compare life expectancy based on
sex, reliability of diagnoses, organ system, disease pro-
cesses and specific diagnoses. Comparison of survival
curves between dogs with different characteristics (such as
cohort year, sex, organ system, disease process) was per-
formed using log rank tests. Hazard ratios for the event
death for specific dichotomous variables were calculated
using the logrank test calculations of hazard rates derived
from the cumulative hazard function of the Kaplan-Meier
curves [17]. The association between specific diseases and
sex was evaluated using a chi-squared test. Where a sig-
nificant difference was found, the relative risk and odds
ratios of male and female dogs for the specific disease
were calculated, whereby the outcome variable was
presence or absence of the specific disease as the cause
of death and group was selected as male or female. Sig-
nificance was set as P = 0.05 throughout.
Results
Population and sample characteristics
From the original target population of 402 dogs, 13 were
excluded due to missing data or because owners could
not be contacted or declined study participation. The tar-
get population of 389 dogs therefore represented 30.2 % of
a total of 1290 BMDs born in 2001 or 2002 and registered
by the Swiss Bernese Mountain Dog Club. Of these,
169/389 (43.4 %) and 220/389 (56.6 %) were born in
2001 and 2002, respectively. There were 227/389 (58.4 %)
female (108 spayed, 31 intact, 88 unknown) and 162/389
male (48 intact, 53 castrated, 61 unknown) animals.
At the end of the study, 381/389 dogs were dead and
8/389 were alive (2.1 %, censored data). No distinction was
made between dogs that died naturally and those eutha-
nised. Data was available for 196 dogs from the previous
study [16] and a further 130 dogs whose owners partici-
pated in the present study. In addition, data was available
for 36 dogs from the Swiss Bernese Mountain Dog Club’s
internal surveillance and data solely regarding the date of
death of 27 dogs was available from the ANIS database.
Dogs that were dead at the end of the study, died at
between 0.7 and 13.0 years of age. Dogs alive at the end
of the study were between 11.5 and 12.7 years old. The
mean and median survival for the entire study population
was 8.25 years (95 % confidence interval (CI), 8.03–8.47)
and 8.40 years (interquartile range (IQR), 6.89–9.66),
respectively. No difference in life expectancy was found
between dogs born in 2001 and those born in 2002
(P = 0.575). For all 389 dogs, females had a significantly
longer life expectancy than males (P < 0.001) (Table 1,
Fig. 1). Moreover, 7 of the 8 dogs alive at the end of the
study were female. For dogs with known gonadectomy
status (n = 310), significantly more females than males
were neutered (P < 0.001). A significant difference in
survival was found between the groups based on sex
and gonadectomy status (P = 0.005) (Table 1, Fig. 1). No
significant difference was found in survival between in-
tact males and intact females (hazard ratio, 1.22 (95 %
CI, 0.87–1.72); P = 0.225), between intact males and
castrated males (hazard ratio, 1.18 (95 % CI, 0.82–1.71);
P = 0.376), or between intact females and spayed females
(hazard ratio, 1.19 (95 % CI, 0.90–1.58); P = 0.221). How-
ever, a significant difference was found between castrated
males and spayed females (hazard ratio, 1.72 (95 % CI,
1.20–2.46); P = 0.001), castrated males having a higher
hazard than spayed females (Table 1, Fig. 1).
Table 1 Mean and median survival of male and female Bernese mountain dogs
Factor Sex N Survival (years) P (logrank)
Mean 95 % CI Median IQR
All dogs All 389 8.25 8.03–8.47 8.40 6.89–9.66
Male 162 7.80 7.49–8.12 7.73 6.62–9.29 <0.000
Female 227 8.57 8.28–8.86 8.78 7.07–10.27
Dogs with known
gonadectomy status
All 304 8.34 8.09–8.59 8.51 6.91–9.82
Male intact 60 7.60 7.05–8.16 7.65 6.47–9.24 0.005
Male castrated 53 8.18 7.67–8.69 8.53 7.23–9.45
Female intact 85 8.85 8.39–9.31 9.36 7.33–10.52
Female spayed 106 8.38 7.97–8.80 8.50 7.00–9.52
Dogs with neoplasia All 222 7.87 7.61–8.12 7.83 6.68–9.25
Male 104 7.50 7.17–7.82 7.41 6.47–8.68 <0.001
Female 118 8.19 7.81–8.57 8.33 6.81–9.64
Dogs with other disorders All 70 7.78 7.23–8.78 8.00 6.74–9.29
Male 29 7.79 6.81–8.76 8.10 6.89–9.24 0.609
Female 41 7.77 7.11–8.43 7.88 6.69–9.47
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Reliability of diagnoses
Of the 381 dogs that died by the end of the study, the
reliability of diagnoses for the cause of death was cate-
gorized as poor in 183/381 dogs (48.0 %), moderate in
56/381 dogs (14.7 %), high in 91/381 dogs (23.9 %) and
excellent in 51/381 dogs (13.4 %). The poor reliability
category included 89 dogs for which the cause of death
was unknown. The median life expectancy was 9.24
(IQR, 7.94–10.44), 8.17 (IQR, 6.96–9.19), 7.18 (IQR,
6.15–8.44) and 7.17 (IQR, 5.91–8.14) years for diagno-
ses with poor, moderate, high and excellent diagnoses,
respectively.
Causes of death
Specific causes of death recorded in more than 5 dogs were
neoplasia (n = 222), degenerative joint disease (n = 16),
spinal disease (n = 13), renal injury (n = 12), and gastric
or mesenteric volvulus (n = 7).
Organ systems
An organ system associated with the causes of death was
allocated in 258 dogs and unknown in 123 dogs. The
most frequently allocated organ systems were multiorgan,
haemolymphatic and respiratory (Table 2). No causes of
death were associated with integumentary or ocular sys-
tems. A single case of mediastinal disease was allocated to
the group of other organ systems. For organ systems with
at least 10 cases, a significantly shorter survival was found
for multiorgan, haemolymphatic and urogenital systems
compared to all other systems excluding unknown cases
(Table 3, Fig. 2). A neoplastic pathologic process was
involved in 60/62 and 41/51 cases of multiorgan and
hemolymphatic involvement, respectively. The shortest
survival was associated with disorders of the urogenital
system, of which 12/14 were attributed to symptomatic
conditions due to acute or chronic kidney injury.
Disease processes and specific disorders
No data was available for the disease process attributed
to the cause of death in 89/381 dogs. For the remaining
dogs, the most frequent process was neoplastic (222/381
dogs, 76.0 %) (Table 2). A further 37/381 dogs died with
symptomatic conditions, most frequently associated with
spinal disorders (para- or tetraplegia/paresis) (n = 13), acute
or chronic kidney injury (n = 12) and anaemia (n = 5).
All degenerative processes were attributed to degenera-
tive joint disease and/or cruciate ligament failure. Mech-
anical processes were due to gastric or mesenteric
volvulus. Immune-mediated processes were most fre-
quently immune-mediated haemolytic anaemia (4 of 5
cases). Only 2 cases were attributed to inflammatory/in-
fectious or metabolic/toxic processes, respectively, and a
single case was attributed to trauma. No cause of death
was attributed to idiopathic, congenital or alimentary
disease processes. For disease processes with at least 5
cases, the shortest survival was associated with immune-
mediated processes, followed by neoplastic processes
(Table 4, Fig. 3). However, immune-mediated processes
were diagnosed in only 5 cases. For specific diseases with
at least 5 cases, renal injury was associated with the
shortest survival, followed by neoplasia (Table 5, Fig. 4).
Fig. 1 Kaplan-Meier survival curves for Bernese mountain dogs based on sex
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Table 2 Organ systems and disease processes associated with the cause of death in Bernese mountain dogs
Organ system Disease process Total
Degenerative Immune-mediated Inflammatory/ infectious Metabolic/ toxic Neoplastic Symptomatic Mechanical Traumatic Unknown
Haemolymphatic 0 4 0 1 41 5 0 0 0 51 (13.4 %)
Nervous 0 0 0 0 5 17 0 0 0 22 (5.8 %)
Cardiovascular 0 0 0 0 1 2 0 0 0 3 (0.8 %)
Endocrine 0 0 0 1 1 0 0 0 0 2 (0.5 %)
Gastrointestinal 0 1 1 0 14 0 7 0 0 23 (6.0 %)
Musculoskeletal 16 0 0 0 21 0 0 0 0 37 (9.7 %)
Multiorgan 0 0 0 0 60 1 0 1 0 62 (16.3 %)
Other 0 0 0 0 1 0 0 0 0 1 (0.3 %)
Respiratory 0 0 1 0 42 0 0 0 0 43 (11.3 %)
Urogenital 0 0 0 0 2 12 0 0 0 14 (3.7 %)
Unknown 0 0 0 0 34 0 0 0 89 123 (32.3 %)
Total 16 (4.2 %) 5 (1.3 %) 2 (0.5 %) 2 (0.5 %) 222 (58.3 %) 37 (9.7 %) 7 (1.8 %) 1 (0.3 %) 89 (23.4 %) 381
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Neoplasia
Specific neoplasms diagnosed in the 222 dogs that died
due to a neoplastic process were HS in 23/222 dogs
(10.4 %), lymphoma in 15/222 dogs (6.8 %) and osteosar-
coma in 11/222 dogs (5.0 %). Other tumours diagnosed
on cytology or histology were sarcoma not further differ-
entiated (n = 4), leukaemia (n = 4), fibrosarcoma (n = 2),
haemangiosarcoma (n = 2), mast cell tumour (n = 2), tran-
sitional cell carcinoma (n = 1) and chondroma (n = 1). The
remainder of neoplasms (unconfirmed on cytology or hist-
ology) were multiorgan tumours (n = 45), lung tumours
(n = 29), splenic tumours (n = 14), liver tumours (n = 6),
oropharyngeal tumours (n = 3), nervous system tumours
(n = 2), intestinal tumours (n = 2), and 1 each of tumours
involving the urinary bladder, heart base, hypophysis, medi-
astinum, nasal cavity, prostate, spine, and axial skeleton.
Histiocytic sarcomas involved the haemolymphatic,
musculoskeletal, respiratory and multiorgan systems, and
were diagnosed in 16 males and 7 females. Lymphoma in-
volved the haemolymphatic and multiorgan systems, and
was diagnosed in 8 males and 7 females. Osteosarcomas
all involved the musculoskeletal system and were diag-
nosed in 6 males and 5 females.
A cause of death due to neoplasia was attributed to a
significantly greater proportion of male dogs (104/161;
64.6 %) than female dogs (118/220; 53.6 %) (P = 0.042).
Male dogs had a relative risk of neoplasia of 1.20 (95 % CI,
1.02–1.42) compared to females (P = 0.030), and an odds
ratio of 1.58 (95 % CI, 1.04–2.40) compared to females
(P = 0.033). Moreover, male dogs with neoplasia had a
shorter survival than female dogs with neoplasia (Table 1).
In addition, male dogs had a relative risk of HS of 3.13
(95 % CI, 1.32–7.42) compared to females (P = 0.010) and
an odds ratio of 3.36 (95 % CI, 1.35–8.37) compared to
Table 3 Comparison of survival based on the organ system
associated with death in Bernese mountain dogs
Organ systema N (%) Survival (years) P (logrank)b
Median IQR
Gastrointestinal 23 (9.1) 8.96 8.96–9.60 0.162
Musculoskeletal 37 (14.7) 8.87 7.54–9.85 0.106
Nervous 22 (8.7) 8.45 7.44–9.29 0.126
Respiratory 43 (17.1) 8.07 6.75–9.54 0.154
Overall 252 (100) 7.85 6.67–9.12
Multiorgan 62 (24.6) 7.41 6.57–8.39 0.006
Haemolymphatic 51 (20.2) 7.34 6.05–8.76 0.048
Urogenital 14 (5.6) 6.76 4.61–8.56 0.033
aexcluding cases with unknown organ systems and organ systems with less
than 5 cases
blog rank test comparing each organ system to all others
Fig. 2 Boxplots showing survival of Bernese mountain dogs based on the organ system attributed to the cause of death
Table 4 Comparison of survival for disease processes associated
with death in Bernese mountain dogs
Disease processa N (%) Survival (years) P (logrank)b
Median IQR
Mechanical 7 (2.4) 9.13 7.36–9.27 0.707
Degenerative 16 (5.6) 8.87 7.62–9.95 0.334
Overall 287 (100) 7.89 6.76–9.27
Symptomatic 37 (12.9) 7.89 6.96–9.08 0.898
Neoplastic 222 (77.4) 7.83 6.68–9.25 0.723
Immune-mediated 5 (1.7) 6.04 5.93–7.46 0.007
aexcluding cases with unknown disease processes and disorders with less
than 5 cases
blog rank test comparing each disease process to all others
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females (P = 0.009). However, no significant difference in
survival was detected between male and female dogs with
HS, lymphoma or osteosarcoma. The median survival was
7.17 years (IQR, 6.50–7.84; range, 3.49 to 10.75) for dogs
with HS, 7.32 years (IQR, 5.91–8.66; range 5.15 to
9.68 years) for dogs with lymphoma, and 8.74 years (IQR,
7.09–9.30; range, 4.74–10.65) for dogs with osteosarcoma.
Discussion
The overall mean (8.25 years) and median (8.40 years)
life expectancy of BMDs in the present study was higher
than that reported in most studies. However, life expect-
ancy of BMDs appears to have increased over time from
5.7 years [18] and 6.8 years [5] in early studies to between
7.0 and 8.0 years in recent years [1, 4, 7, 19]. This apparent
increase in life expectancy was also noted in previous
studies and has been attributed to more advanced
veterinary care and an increasing social value of dogs
[5, 20]. Despite this increase, the BMD remains in the
group of dogs with a relatively low life expectancy
compared to breed-independent values, estimated to
be a mean of 10.0 years [5] or a median of 11.0 years
[6, 21]. The age at death used in data analysis in the
present study was based on pedigree records from the
Swiss Bernese Mountain Dog Club for the date of birth
and the date reported by veterinarians or owners for
the date of death. The accuracy of the date of death re-
ported could not be verified.
The low life expectancy in the BMD has been attributed
to a high prevalence of neoplasia, reported to be between
26.1 % and 55.1 % [1, 3–5, 18, 19, 22], compared to other
purebred and general dog populations, in which tumour
prevalence is estimated between 14.5 % and 27 % [1, 6,
21]. Data in the present study corroborates these findings
with death due to neoplasia in 58.3 % of the target popula-
tion. This was somewhat higher than previously reported.
However, the reliability of diagnoses in the present study
was highly variable, and most cases with a diagnosis of
neoplasia were not confirmed on cytology or histology.
The true incidence of neoplastic disorders is therefore
likely to be somewhat lower or higher than that found
in the present study.
Female BMDs in the present study had a higher life
expectancy than males, corroborating findings of a pre-
vious study in which female BMDs were reported to live
about 1 year longer than males [5]. Although a higher
hazard ratio was found for intact males compared to in-
tact and spayed females, and castrated males compared
to intact females, this was not detected for castrated
males compared to spayed females. However, a large
Fig. 3 Boxplots showing survival of Bernese mountain dogs based on the disease process attributed to the cause of death
Table 5 Comparison of survival for specific disorders associated
with death in Bernese mountain dogs
Specific disordera N (%) Survival (years) P (logrank)b
Median IQR
Gastric or
mesenteric volvulus
7 (2.9) 9.13 7.36–9.91 0.733
Degenerative
joint disease
16 (5.9) 8.87 7.59–9.95 0.352
Spinal disorder 13 (4.8) 8.35 7.33–10.19 0.206
Overall 270 (100) 7.93 6.76–9.29
Neoplasia 222 (82.2) 7.83 6.68–9.25 0.445
Renal injury
(acute or chronic)
12 (4.4) 6.83 4.19–8.56 0.047
aexcluding cases with unknown disorders and disorders with less than 5 cases
blog rank test comparing each disease to all others
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proportion of dogs, for which the gonadectomy status
was unknown, was excluded from this analysis. More-
over, the time at which gonadectomy took place was not
taken into consideration. The effect, if any, of long-term
presence or absence of sex hormones on survival is
therefore unclear. Possible explanations for longer sur-
vival in females include a generally higher life expec-
tancy in female dogs, as well as the higher risk of
neoplasia in males and the associated lower survival in
males in the present study. This finding contradicts
findings of a previous study in which no difference in
risk of neoplasia was found between males and females
[4]. Moreover, it is in contrast to findings of different
cancer registries, which reveal a predisposition for all
neoplasms in female dogs [2, 5, 23]. However, this fe-
male predisposition is largely due to mammary cancer,
which was not found in any of the dogs in the present
study and was found to have a low prevalence in BMDs
in a previous study [5]. This finding suggests that, al-
though BMDs may be predisposed to some neoplasms,
they may have a diminished risk for certain other types
of neoplastic disorders or simply not live long enough
for neoplasms associated with high age.
The most frequently diagnosed neoplasia in the present
study was HS (10.4 % of all neoplasms). This was similar
to previous investigations in Dutch and Norwegian BMD
populations, in which HS accounted for 15.3 % [4] and
10.7 % [7], respectively. In a study of BMDs presented to a
German university hospital, HS accounted for 8.2 % of
histologically-confirmed tumours but up to 15.7 % when
including tumours not histologically confirmed but highly
suspected based on typical lesion distribution [22]. As the
majority of tumours diagnosed in the present study lacked
histologic confirmation and many dogs died without
any diagnosis, the true prevalence in this population is
unclear.
Of dogs with confirmed HS, the median survival of
7.2 years was somewhat higher than the previously
reported 6.3 years [4]. Previous studies reported a wide
range of ages of BMDs diagnosed with HS with one
report of dogs aged between 10 months and 14.7 years
with the majority between 5 and 8 years old [22]. Find-
ings in the present study were similar with nearly half of
the dogs dying between 7 and 8 years old with a range
between 3.5 and 10.8 years old. The higher relative risk
of male dogs with HS in the present study does not
corroborate findings of previous recent studies in which
females were reported with a higher prevalence or no
difference in sex was found [11, 12, 22]. The reason for
this apparent discrepancy is unclear but the large num-
bers of dogs in the present study for which no cause of
death was available introduces a large uncertainty with
regards to disease prevalence and sex distributions.
Lymphoma was the second most commonly identified
cancer, corroborating findings in previous studies [22].
With regards to non-neoplastic disease processes, dogs
with symptomatic conditions included 13 dogs that were
euthanised or died with paraparesis, paraplegia or tetra-
paresis. The median life expectancy of these dogs was
8.4 years, suggesting that at least some of these dogs may
have suffered from degenerative myelopathy, previously
described in older dogs of this breed [24]. However, this
cannot be confirmed as post-mortem histopathology was
not performed in any of these dogs. The BMDs with uro-
genital disorders had the shortest life span and most were
attributed symptomatically to chronic or acute kidney
Fig. 4 Kaplan-Meier survival curves for Bernese mountain dogs based on causes of death
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injury. The extent to which any of these dogs was affected
by hereditary membranoproliferative glomerulopathy in
this breed is unclear [25, 26]. All in all, the 3.6 % of deaths
due to kidney injury is somewhat lower (6.9 %) than in
a previous report [7]. Five dogs suffered from immune-
mediated diseases, of which 4 were diagnosed with
immune-mediated haemolytic anaemia or Evans syn-
drome, resulting in a particularly low life expectancy in
this disease process group. However, the number of
dogs was very low and the degree to which an under-
lying neoplastic process was ruled out is not known.
In contrast to 1 previous study [7], cardiovascular dis-
eases, behavioural problems, and infectious diseases oc-
curred extremely rarely or not at all in our limited
sample population. However, behavioural problems as
cause of death (euthanasia) might not have been re-
ported, as euthanasia for this reason is considered
somewhat taboo in our society. In addition, a high vac-
cination coverage for common infectious diseases in
Switzerland and good access to veterinary care might
diminish the rate of lethal infectious diseases. More-
over, treatment of disorders such as degenerative joint
diseases may significantly diminish their prevalence as
a cause of death even though they may be widespread
chronic disorders within the population. As the present
study only evaluated diseases associated with death, the
data cannot therefore be interpreted as general preva-
lence data.
The reason for a short lifespan in the BMD is likely
multifactorial but significant factors include the high
prevalence of tumours, as only few other breeds, includ-
ing flat-coated retrievers and boxers, exhibit a compar-
able high prevalence [2–4]. Furthermore, BMDs with
neoplasia died with a median age of 1.2 years younger
than those that died of causes other than neoplasia in
the present study. The shorter life span for dogs of lar-
ger body size is an additional factor [1, 8–10, 27–29].
In the present study, information regarding the cause
of death that was purely based on information acquired
from dog owners was considered of low diagnostic reli-
ability. Interestingly, dogs with higher longevity were
more frequently classified in the lowest quality of diag-
noses. In contrast, dogs that died at an early age were
classified in the highest categories. This observation
may suggest that dog owners and veterinarians are
more willing to invest time and money in the work-up
and diagnosis of diseases in dogs presenting at a younger
age. However, it is also possible that far more detailed
data was transmitted by veterinarians when dogs were
euthanized at a younger age.
To the authors’ knowledge, this is the first study to in-
vestigate only purebred BMDs with pedigree born in a
single country and representing a large proportion of all
dogs born within the same period. As the vast majority
of dogs (all but 8) in the present study had died by the
end of the study, bias due to right-censored data was
minimal in the present study. Major limitations of the
study include a relatively large proportion of owners
who chose not to participate or could not be located,
creating possible responder bias. In addition, slightly
over 20 % of dogs died or were euthanised without any
specific diagnosis, and the diagnosis of neoplasia was
mostly made without histologic confirmation. Moreover, a
large proportion of diagnoses were of poor or moderate re-
liability. Possible reasons include unwillingness of owners
to confirm diagnoses in cases of presumed poor prognosis,
and unwillingness to perform post-mortem examinations
in cases in which no specific antemortem diagnosis was
evident. For owners unwilling to perform necropsy for
emotional and/or spiritual reasons, minimally invasive
digital imaging, such as X-Ray, Ultrasound, CT and MRI in
combination with fine needle aspiration and needle biopsy,
may constitute a promising tool to improve post-mortem
diagnoses [30]. In addition, overdiagnosis of neoplasia by
veterinarians because of a perceived high risk of tumours
in BMDs may have artificially inflated prevalence of neo-
plasia in this study. At the same time, some animals with
unknown cases of death or those dying with only symp-
tomatic diagnoses may indeed have had undiscovered neo-
plasia, leading to underestimation of its true prevalence.
Besides analyses on the causes of death, the collection
of health histories from birth to death, as well as clinical
and genetic material for analyses of specific diseases may
be valuable to more precisely assess breed health. Fur-
ther studies, prospectively collecting health data from
defined health populations or cohorts may enable breed-
ing clubs to more accurately assess breed health.
Conclusions
This study confirms the high prevalence of neoplasia in
BMDs. Although the prevalence may be overestimated
due to the lacking histological or cytological confirm-
ation, neoplasia is an important factor for the low life
expectancy in BMDs.
The diagnostic accuracy leaves much to be desired and
further research on malignant processes with a high diag-
nostic standard is necessary to improve breed health.
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